中国全科医学 ›› 2019, Vol. 22 ›› Issue (17): 2091-2098.DOI: 10.12114/j.issn.1007-9572.2019.00.017

• 专题研究 • 上一篇    下一篇

荆花胃康联合三联或四联疗法与四联疗法对比治疗幽门螺杆菌相关慢性胃炎或消化性溃疡有效性和安全性的Meta分析

杨佳卉1,2,梁雨1,2,罗培培1,2,和水祥1*   

  1. 1.710061陕西省西安市,西安交通大学第一附属医院 2.710061陕西省西安市,西安交通大学医学部
    *通信作者:和水祥,教授,博士生导师;E-mail:dyyyjxk@mail.xjtu.edu.com
  • 出版日期:2019-06-15 发布日期:2019-06-15

Efficacy and Safety of Jinghua Weikang Combined with Triple or Quadruple Therapy in the Treatment of Helicobacter Pylori Associated Chronic Gastritis or Peptic Ulcer:a Meta-analysis 

YANG Jiahui1,2,LIANG Yu1,2,LUO Peipei1,2,HE Shuixiang1*   

  1. 1.The First Affiliated Hospital of Xi'an Jiaotong University,Xi'an 710061,China
    2.Medical College,Xi'an Jiaotong University,Xi'an 710061,China
    *Corresponding author:HE Shuixiang,Professor,Doctoral supervisor;E-mail:dyyyjxk@mail.xjtu.edu.com
  • Published:2019-06-15 Online:2019-06-15

摘要: 背景 幽门螺杆菌(Hp)感染与慢性胃炎及消化性溃疡密切相关,根除Hp是治疗相关疾病的关键环节。然而抗生素耐药率不断升高,部分中药显示出有效的杀菌、抑菌作用,中药联合西药治疗是否能提高Hp根除率日益受到关注。目的 系统评价荆花胃康联合三联或四联疗法与四联疗法对比治疗Hp相关慢性胃炎或消化性溃疡有效性和安全性。方法 计算机检索中国知网(CNKI)、维普网(VIP)、万方数据知识服务平台、中国生物医学文献数据库(CBM)、PubMed、Ovid-EMBase等数据库,收集荆花胃康联合三联或四联疗法(试验组)与四联疗法(对照组)对比治疗Hp相关慢性胃炎或消化性溃疡的随机对照研究,检索时间限定为建库至2018年4月。由两名研究者按纳入标准独立筛选文献、提取资料并进行方法学质量评价,并采用RevMan 5.2 及STATA 14.0软件进行Meta分析。结果 共纳入21篇文献,2 974例患者。Meta分析结果显示,荆花胃康联合三联疗法对比四联疗法,试验组与对照组Hp根除率比较,差异均无统计学意义〔RR=0.98,95%CI(0.94,1.02),P=0.35〕;试验组不良反应发生率较对照组降低〔RR=0.39,95%CI(0.26,0.58),P<0.000 01〕;试验组消化道相关症状改善有效率较对照组升高〔RR=1.31,95%CI(1.14,1.51),P=0.000 2〕。荆花胃康联合四联疗法对比四联疗法,试验组Hp根除率较对照组升高〔RR=1.16,95%CI(1.08,1.24),P<0.000 1〕;试验组不良反应发生率较对照组降低〔RR=0.36,95%CI(0.15,0.82),P=0.02〕;试验组与对照组消化道相关症状改善有效率比较,差异无统计学意义〔RR=1.15,95%CI(0.97,1.36),P=0.12〕。结论 荆花胃康联合三联疗法的Hp根除率与四联疗法相当,且消化道相关症状改善有效率优于四联疗法,同时减少了不良反应。荆花胃康联合四联疗法与单用四联疗法相比根除Hp的疗效更佳,消化道相关症状改善有效率与四联疗法相当,但不良反应明显减少,可为临床用药提供参考。

关键词: 胃炎, 消化性溃疡, 铋, 幽门螺杆菌, 荆花胃康, Meta分析

Abstract: Background Helicobacter pylori (Hp) infection is closely related to chronic gastritis and certain types of peptic ulcer,and eradication of Hp is a key link in the treatment of related diseases.However,due to the increasing drug resistance rate of antibody treatment and the effective bactericidal and bacteriostatic effect of some traditional Chinese medicine,whether the combination of traditional Chinese medicine and western medicine can improve the eradication rate of Hp is increasingly concerned.Objective To systematically evaluate the efficacy and safety of Jinghua Weikang combined with triple or quadruple therapy compared with standard quadruple therapy in the treatment of Hp related chronic gastritis or peptic ulcer.Methods The databases,such as CNKI,VIP,Wanfang Data Knowledge Service Platform,CBM,PubMed and Ovid-EMBase were retrieved.They were searched from the establishment of databases to April 2018 to identify the randomized controlled trials (RCTs) of Jinghua Weikang capsules combined with triple or quadruple therapy compared with quadruple therapy in the treatment of Hp-associated chronic gastritis or peptic ulcer.Then studies were identified according to predefined inclusion and exclusion criteria,and their quality was evaluated by two researchers separately.The meta-analysis was performed using RevMan 5.2 and STATA 14.0 software.Results Twenty-one studies involving 2 974 patients were included.The results of meta-analysis showed that there was no significant difference in Hp eradication rate between the experimental group of Jinghua Weikang combined with triple regimen and control group of quadruple therapy 〔RR=0.98,95%CI(0.94,1.02),P=0.35〕;the incidence of adverse reactions in the experimental group was lower than that in the control group 〔RR=0.39,95%CI(0.26,0.58),P<0.000 01〕;the improvement of digestive tract-related symptoms in the experimental group was higher than that in the control group 〔RR=1.31,95%CI(1.14,1.51),P=0.000 2〕.The eradication rate of Hp in the experimental group of Jinghua Weikang combined with quadruple therapy was higher than that in the control group of quadruple therapy 〔RR=1.16,95%CI(1.08,1.24),P<0.000 1〕;the incidence of adverse reactions in the experimental group was lower than that in the control group 〔RR=0.36,95%CI(0.15,0.82),P=0.02〕.There was no significant difference in the improvement of digestive tract-related symptoms between the experimental group and the control group 〔RR=1.15,95%CI(0.97,1.36),P=0.12〕.Conclusion The Hp eradication rate of Jinghua Weikang combined with triple therapy was comparable to that of standard quadruple therapy,with better symptom improvement and reduced adverse reactions.Compared with the single quadruple therapy,Jinghua Weikang combined with quadruple therapy has better efficacy in eradicating Hp,and the improvement of symptoms is comparable,but the adverse reactions are significantly reduced.Our study could provide reference for clinical medication.

Key words: Gastritis, Peptic ulcer, Bismuth, Helicobacter pylori, Jinghua Weikang, Meta-analysis